In 2006 Dr. Ellies founded OsteoGeneX Inc (OGX), and has worked to develop the unique business strategy for a strategic partner to get market revenue quickly, with a de-risked efficacious orally available drug that will increase bone density. Prior to launching OGX, Dr. Ellies was at the Stowers Medical Research Institute in Kansas City, MO. While at the Stowers Institute under the direction of Dr Krumlauf, Debra was the key scientist in the epochal discovery of Sclerostin as a modulator of the WNT pathway. Dr. Ellies was also part of the scientific team which discovered that the CCN family also functioned via WNT signaling. Furthermore, Ellies & Krumlauf were the first to report that Sclerostin blocking antibodies function by blocking the WNT pathway. Prior to her work at Stowers, Dr. Ellies conducted basic research on the developmental significance of programmed cell death, the role in Wnt signaling and managed a laboratory at Ottawa Civic Hospital in Ottawa, Canada. In addition to her remarkable successes in the laboratory, Dr. Ellies co-founded the Brian Ellies Esophageal Cancer Prevention Fund, which works to educate the public and promote awareness of esophageal cancer prevention. Dr. Ellies is the author of several international key scientific manuscripts in the area of signal transduction, and of a number of patents, and a reviewer for Center for Scientific Reviewer at NIH, and a Trustee for MRIGlobal. She received her Ph.D. from Guy’s Hospital London, UK, under the supervision of Prof. Andrew Lumsden, FRS; M.Sc. from University Ottawa, LOEB Research Institute, Canada.
Harold Rosen, M.D., is the Director of the Osteoporosis Prevention and Treatment Center at Harvard Beth Israel Deaconess Medical Center, which provides state-of-the-art bone densitometry and consultation regarding osteoporosis and other metabolic bone diseases. Dr. Rosen is an endocrinologist specializing in osteoporosis and other metabolic bone diseases, such as the osteomalacia that can occur with celiac disease. Dr. Rosen attended the Albert Einstein College of Medicine and graduated with distinction in research in Endocrinology. He did his Internship in Internal Medicine at Montefiore Hospital and his residency in Internal Medicine at the University of Cincinnati Medical Center. He did fellowships in endocrinology and Geriatrics at Beth Israel Hospital in Boston, and remained there as faculty, doing clinical research in osteoporosis.
James Macdonald, Ph.D. joined OGX in 2009 as advisor. During a three decade career, Dr. MacDonald has brought hundreds of new molecular entities forward from discovery into development, over thirty of which have become globally registered, major drugs, including Fosamax® (for osteoporosis), Vasotec®, Zocor®, Primaxin®, Clinoril®, Pepcid®, Clarinex®, Nasonex®, and Vitorin®, among others. Until his retirement in 2008, he was Executive VP of Preclinical Development for Schering-Plough Research Institute (SPRI), the pharmaceutical development arm of Schering Corporation. Joining SPRI in 1994, over the next 14 years Dr. MacDonald played a leading role in building one of the most capable drug development organizations in the world. In addition to his line of responsibility for Drug Safety and Metabolism, as co-chairman of SPRI’s Early Development Committee he directed the activities surrounding the movement of drug candidates from discovery research into and through the development process.
Nancy Lane, M.D., is an Endowed Professor of Medicine, Rheumatology and Aging at the University of California, Davis Medical School in Sacramento,California. She is leading investigator in research on osteoporosis having participated in ground breaking studies with parathyroid hormone and the pathobiology of bone fragility. She was the President of the U.S. Bone and Joint Decade Board from 2005-2007, and is on the editorial board of the Journal of Bone and Mineral Research, Osteoporosis International, and Arthritis Research, Nature Clinical Practice Rheumatology and co-editor of Arthritis and Rheumatism. She is also a consultant reviewer for numerous peer-reviewed journals, among them JAMA, Annals of Internal Medicine, and Journal of Bone and Joint Surgery. Dr. Lane is a frequent lecturer on osteoporosis and the author of hundreds of journal articles, book chapters, books such The Osteoporosis Book, a guide for patients and their family, and abstracts.
Robert Young, Ph.D. Joined OGX in 2009 as advisor. Merck Frost–B.C. Discovery Chair in Pharmaceutical Genomics, Bioinformatics and Drug Discovery, Simon Fraser University, Canada. He received his PhD under Professor James Kutney at the University of British Columbia in 1971. He then trained with Professor Sir Derek H.R. Barton at Imperial College of Science and Technology, London, and the University of Adelaide, Adelaide, South Australia, working with Professor David Hamon, and at the Institut de Chimie des Substances Naturelles (CNRS), Gif-sur-Yvette, France. Dr Young then spent over three decades at Merck Frosst Canada, from senior research chemist to Vice-President, Medicinal Chemistry. Dr. Young has been involved in the discovery of a number of important new drugs including Singulair® for asthma and Vioxx® and Arcoxia™ for inflammation. He has authored over 100 publications, review articles and 50 patents. In 2006 Dr. Young retired from Merck Frosst and formed a consulting company, Promorpheus Consultants Inc., offering services in Medicinal Chemistry and Drug Discovery. In April 2007 Dr. Young took up a position as B.C. Research Chair at the Simon Fraser University, Burnaby, B.C. pursuing research in Chemical Genomics and Drug Discovery.